Pharmacotherapy
Clinician's Perspective: • Users of GLP-1 receptor agonists may experience a three-fold higher risk of hair, however, the overall incidence is still very low. • Research into Semaglutide reveals that hair loss is rarely reported at the lower doses (0.25mg to 2mg) typically used for diabetes, but becomes more
Pharmacotherapy
Clinician's Perspective: • In Singapore, it is estimated that 12.7% of the population has a BMI of 30 or higher, a significant 22.8% of residents fall into the high-risk category (BMI ≥27.5) due to the higher risk of cardiovascular disease in Asian populations. • Healthy diet is
Pharmacotherapy
Clinician's Perspective: • Semaglutide is a GLP-1 (Glucagon-like Peptide-1) receptor agonist that mimics a natural hormone to regulate appetite and improve insulin secretion, making it a cornerstone therapy for both Type 2 Diabetes and chronic weight management. • Weight Reduction: Participants using 2.4 mg of Semaglutide lost an average
Pharmacotherapy
Clinician's Perspective: • Tirzepatide is a medication that targets two distinct hormone receptors: the Glucagon-like Peptide-1 (GLP-1) and the Glucose-dependent Insulinotropic Polypeptide (GIP). As a result, the stomach emptying is slowed down and appetite is reduced. • Dose-Dependent Weight Loss: Across clinical trials lasting 72 weeks, participants achieved total body
Pharmacotherapy
Clinician's Perspective: • Researchers identified a specific genetic variant in the GLP1R gene (GLP-1 receptor) (the primary cellular docking site for these drugs) that directly influences how much weight a person loses. • Individuals carrying a specific version of this gene (rs10305420) experienced an additional 0.76 kg of weight
Pharmacotherapy
Clinician's Perspective: • Modern anti-obesity medications (AOM) function by modulating central appetite signaling, delaying gastric emptying, or inhibiting lipid absorption in the gastrointestinal tract. • In Singapore, typical medical criterion for AOM treatment include a Body Mass Index (BMI) of 27.5 or higher in the presence of weight-related comorbidities
Pharmacotherapy
Clinician's Perspective: • Hormonal Mimicry: GLP-1 agonists function by mimicking the Glucagon-like peptide-1 hormone, a naturally occurring substance produced in the small intestine that regulates insulin and satiety (the feeling of fullness). • Glucose Modulation: These agents trigger insulin release and block glucagon secretion, effectively preventing blood sugar spikes and
Pharmacotherapy
Clinician's Perspective: • Combined Potency: Bupropion combined with Naltrexone demonstrated superior weight reduction compared to Bupropion monotherapy (the use of a single drug). • Absolute Weight Loss: The meta-analysis, involving over 22,000 participants, revealed a mean weight reduction of 3.67 kg across the intervention groups compared to controls.
Pharmacotherapy
Clinician's Perspective: • Synergistic Weight Loss: Combining phentermine and topiramate-ER (extended-release) provides a more robust weight reduction than either drug used alone by targeting different metabolic pathways. • Significant Results: In the EQUIP trial involving 1,267 participants, the high-dose group achieved an average weight loss of 14.4% of